---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-035882"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:48:51.055770+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials

## Summary
- Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.
- TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.
- Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.
- R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).
- Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials.

## SEC filing metadata
- accession: 0001193125-25-035882
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/0001193125-25-035882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-035882
- JSON: https://secwatch.observer/filing/0001193125-25-035882.json
- Plain text: https://secwatch.observer/filing/0001193125-25-035882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.